Notice: This publication is an educational and analytical reference document intended strictly for scientific researchers, academic institutions, and qualified laboratory personnel in the United Kingdom. Retatrutide (LY3437943) is supplied exclusively as a non-clinical biochemical reference standard for in-vitro research and laboratory experimentation. It is not approved as a human medicinal product, veterinary substance, food additive, or cosmetic ingredient.
Quick-Reference Specifications: Retatrutide (LY3437943)
| Property | Scientific Specification |
|---|---|
| Chemical Name | Retatrutide (investigational code: LY3437943) |
| Pharmacological Class | Synthetic acylated unimolecular peptide triple agonist |
| Amino Acid Length | 39 amino acids (acylated peptide backbone) |
| Primary Receptor Targets | GIPR (GIP receptor), GLP-1R (GLP-1 receptor), GCGR (Glucagon receptor) |
| Molecular Formula | C221H342N48O68 |
| Monoisotopic Molecular Weight | ~4,731.33 Da (approx. 4.73 kDa) |
| CAS Registry Number | 2381089-83-2 |
| Physical Appearance | White to off-white lyophilised solid / sterile vacuum cake |
| Recommended Storage (Lyophilised) | -20°C protected from light and atmospheric moisture |
| Working Solution Life (Reconstituted) | 2°C to 8°C (use within 21 to 28 days; avoid repeated freezing) |
| UK Legal & Regulatory Status | Unapproved research chemical — strictly for in-vitro laboratory research (RUO) |
What is Retatrutide (LY3437943)?
Direct Answer: Retatrutide (development code LY3437943) is a synthetic 39-amino-acid acylated unimolecular peptide engineered to concurrently activate three metabolic G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor. Developed through rational peptide engineering, Retatrutide provides laboratory investigators with a specialized chemical tool to study multi-incretin signaling, hepatic lipid oxidation, and cellular energy expenditure in preclinical models.
Unlike single-target incretins (such as semaglutide, which selectively targets GLP-1R) or dual-target co-agonists (such as tirzepatide, targeting GIPR and GLP-1R), Retatrutide is classified pharmacologically as a “tri-agonist.” Its synthetic sequence incorporates a 20-carbon fatty diacid moiety that facilitates non-covalent binding to circulating albumin, significantly extending its functional half-life in physiological and cellular experimental systems.
Receptor Affinity & Pharmacological Signaling Mechanisms
The core objective of multi-agonist peptide research is determining how cooperative receptor activation influences intracellular signaling cascades. Published pharmacological assays evaluate Retatrutide across three distinct receptor systems:
- GIP Receptor Agonism (Primary Potency): Retatrutide exhibits high in-vitro potency at the human GIP receptor, stimulating cyclic adenosine monophosphate (cAMP) accumulation in cell lines expressing recombinant GIPR. In preclinical models, GIP signaling modulates insulin secretion in response to glucose while attenuating nausea-related behavioral markers.
- GLP-1 Receptor Agonism (Balanced Potency): At the human GLP-1 receptor, Retatrutide activates downstream adenylate cyclase signaling, promoting cellular insulin gene transcription and delaying gastric emptying in preclinical model assays.
- Glucagon Receptor Agonism (Metabolic Driver): The incorporation of glucagon receptor engagement distinguishes Retatrutide from predecessor incretins. Glucagon receptor signaling promotes hepatic lipolysis, elevates resting energy expenditure, and influences mitochondrial uncoupling in experimental liver and brown adipose tissue models.
| Compound | GIP Receptor | GLP-1 Receptor | Glucagon Receptor | Molecular Class |
|---|---|---|---|---|
| Semaglutide | No activity | Full Agonist | No activity | Mono-agonist (GLP-1R) |
| Tirzepatide | Full Agonist | Balanced Agonist | No activity | Dual co-agonist (GIPR / GLP-1R) |
| Retatrutide | Potent Agonist | Balanced Agonist | Functional Agonist | Triple agonist (GIPR / GLP-1R / GCGR) |
Preclinical Research Insights & In-Vitro Models
Preclinical metabolic investigations utilizing Retatrutide explore several key biological hypotheses:
- Synergistic Receptor Crosstalk: In-vitro cellular models examine whether simultaneous GIP and glucagon receptor activation mitigates the appetite-suppressive plateau observed in mono-agonist experiments.
- Hepatic Lipid Clearance: Cell culture studies on primary hepatocytes evaluate Retatrutide’s ability to stimulate carnitine palmitoyltransferase-1 (CPT-1) expression, a rate-limiting enzyme in mitochondrial fatty acid beta-oxidation.
- Beta-Cell Protection & Secretory Capacity: Isolated pancreatic islet assays assess how dual GIP/GLP-1 activation preserves cellular architecture under glucolipotoxic conditions.
Laboratory Reconstitution & Handling Protocols
Proper analytical handling is essential to preserve the structural integrity of Retatrutide and avoid hydrolytic cleavage or aggregation:
- Equilibration: Before unsealing, allow the frozen lyophilised vial to equilibrate in a desiccator to room temperature (20°C to 22°C) for approximately 30 minutes. This prevents ambient atmospheric humidity from condensing onto the hygroscopic powder.
- Solvent Selection: Utilize analytical-grade sterile bacteriostatic water containing 0.9% benzyl alcohol for multi-dose research protocols, or sterile deionised 0.9% sodium chloride for single-use cell culture assays where preservatives could interfere with cellular viability.
- Aseptic Dilution: Slowly introduce the diluent against the inner glass vial wall rather than dispensing directly onto the lyophilised cake.
- Gentle Dissolution: Swirl the vial gently with a rolling wrist motion. Do not vortex or violently shake the vial, as mechanical shear stress can denature the secondary structure of high-molecular-weight peptides.
- Visual Inspection: Ensure the reconstituted solution is completely clear and free of particulate matter before sampling.
Storage Stability & Cold-Chain Guidelines
Like all complex synthetic peptides, Retatrutide is susceptible to thermal, photochemical, and chemical degradation over time:
- Lyophilised Storage (-20°C): Sealed vials in their dry lyophilised state should be stored at -20°C in an amber or dark container. Under dry, sub-zero conditions, chemical stability is preserved for up to 24 months.
- Short-Term Lyophilised Holding (2°C–8°C): For active laboratory projects, lyophilised vials may be refrigerated at 2°C to 8°C for up to 60 days without significant loss of analytical purity.
- Reconstituted Storage (2°C–8°C): Once in aqueous solution, store the vial refrigerated at 2°C to 8°C and use within 21 to 28 days. Avoid freezing reconstituted solutions repeatedly, as ice crystal formation causes peptide aggregation and loss of potency.
Frequently Asked Questions (FAQ) for Researchers
What is the exact molecular difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual agonist targeting only GIP and GLP-1 receptors. Retatrutide incorporates an acylated amino acid sequence specifically tailored to also activate the glucagon (GCGR) receptor, conferring triple-agonist pharmacodynamics.
What is the molecular weight of Retatrutide?
Retatrutide has a calculated monoisotopic molecular weight of approximately 4,731.33 Da (often rounded to 4,731 g/mol). Exact mass verification in analytical certificates is determined via electrospray ionization mass spectrometry (ESI-MS).
What solvent is recommended for reconstituting Retatrutide?
Analytical laboratories typically reconstitute lyophilised Retatrutide using sterile bacteriostatic water (containing 0.9% benzyl alcohol) for multi-aliquot stability, or sterile 0.9% sodium chloride for acute in-vitro experiments.
Is Retatrutide approved for human clinical use in the UK?
No. Retatrutide is currently an unapproved investigational chemical undergoing global clinical trials. In the United Kingdom, it is supplied strictly for in-vitro scientific study, laboratory experimentation, and analytical reference. It is not licensed for medical or veterinary use.
Related UK Laboratory Resources
- Quality, Sourcing & Laboratory Standards — Review MyPep Biotech’s synthesis standards, batch traceability, and UK laboratory inspection protocols.
- UK Laboratory Peptide Sourcing Guide — Comprehensive procurement guide covering HPLC purity, mass spectrometry, and storage compliance.
- Peptide Reconstitution Guide — Detailed in-vitro diluent protocols, reconstitution calculators, and vial handling instructions.
- UK Research Peptides Catalog — Browse verified laboratory reference standards and precision delivery hardware.
Leave a Reply